Summary: The Economic Dimension of Neglect

ME/CFS is an economically severe disease by any measure: USD 17–24 billion annually in the U.S., AU$14.5 billion in Australia, per-patient costs comparable to MS and RA, employment rates below 27% across studies, indirect costs accounting for two-thirds or more of the total burden, and caregiver economic impact that impoverishes families. Its research funding receives approximately USD 1 for every USD 1,000 in economic cost it generates — a ratio 30–40 times worse than MS or RA.

The economic data are descriptive, not causal — they document the present state, not the return on hypothetical interventions. The most important economic study in ME/CFS has not been done: the cost-effectiveness of reducing diagnostic delay, of funding a sustained research program, or of any care model. The evidence gap is not an accident — it is a predictable consequence of the same structural underinvestment it would quantify if filled.

Synthesis: The Economic Case for ME/CFS

ME/CFS imposes costs of USD 18,000–29,000 per patient per year across three countries with independent cost-of-illness studies. Employment rates cluster around 20% (versus ~80% in the general population). Caregivers experience 50% household-income reductions. Yet the disease receives approximately USD 15M per year in U.S. federal research funding — a 1,000:1 burden-to-funding ratio that is 30–40 times worse than multiple sclerosis or rheumatoid arthritis, diseases with comparable per-patient costs and disability severity.

The economic argument for increased funding has never been stronger — because the data keep accumulating — and never been harder to dismiss — because the cross-disease comparators show the disparity is structural, not attributable to any unique feature of ME/CFS as a research target. The argument’s single vulnerability — that it is descriptive, not causal, and cannot predict the return on a specific funding increase — is itself a product of the underfunding it documents No Formal Return-on-Investment Analysis. The research needed to estimate the ROI of ME/CFS research funding has itself not been funded.

The strongest conclusion the evidence supports is not that a specific funding increase is cost-effective, but that the current funding level is impossible to justify on any cost-effectiveness principle — because the burden is documented, the funding disparity is measured, and no disease of comparable economic severity is funded at ME/CFS levels. A funding level that is unjustifiable on the available evidence is a funding level that should change, regardless of whether the optimal level can be calculated — just as a treatment known to be harmful is withdrawn before its replacement is proven effective.

Consequence: This synthesis translates the chapter’s descriptive economics into a single actionable claim: the current level of ME/CFS research funding is inconsistent with its documented burden. Policy change does not require proving that a specific funding level is optimal — it requires demonstrating that the current level is indefensible. The chapter provides that demonstration. (Certainty: 0.65 — cost-of-illness data from multiple independent studies with convergent estimates across three countries; funding disparity verified against public NIH data; the synthesis translates descriptive evidence into a policy claim, not a causal inference.) Severity applicability: the synthesis applies to the research enterprise as a whole; its policy implications affect patients across all severity levels, with the largest impact on severe and very severe patients who have the greatest need for treatment advances and the least capacity to participate in the research advocacy that would produce them.